Omecamtiv Mecarbil

In collaboration with Amgen, Cytokinetics is developing omecamtiv mecarbil, a novel activator of cardiac myosin, the motor protein that powers cardiac muscle contraction. It is being investigated as a potential treatment for heart failure.

Omecamtiv mecarbil, an investigational drug candidate, is designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance, potentially helping patients preserve cardiac function and quality of life, avoid hospitalizations, and decrease the risk of mortality due to heart failure. Certain current treatments for heart failure improve cardiac muscle performance by increasing cellular concentration of calcium thereby increasing heart rate, blood pressure and arrhythmias (irregular heart rhythms), and ultimately may increase the risk of mortality. Increasing the speed or velocity of muscle contraction may also shorten the duration of systolic ejection time—the time it takes for the blood to leave the heart chamber and enter systemic circulation. Cytokinetics’ cardiac muscle activator stimulates cardiac myosin to increase cardiac performance without increasing cellular calcium concentrations.

Omecamtiv mecarbil was the subject of four Phase 2 clinical trials, including a trial called COSMIC-HF that evaluated oral omecamtiv mecarbil in patients with chronic heart failure and left ventricular systolic dysfunction.

Omecamtiv mecarbil is the subject of a comprehensive Phase 3 clinical trials program comprised of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), a large, Phase 3 global cardiovascular outcomes study, and METEORIC-HF, (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), designed to evaluate the effect of treatment on exercise capacity. Amgen is conducting GALACTIC-HF in collaboration with Cytokinetics and Servier.